Preoperative PNI-dNLR Score as Predicting Long-Term Survival in Older Adults Undergoing Radical Gastrectomy for Gastric Cancer Authors: Xun-Lin Chen, Xin-Mei Zhang, Zhi-Xin Lin, Xiao-Liang Huang, Yi-Zhou Chen, Wei-Zhen Lin, Chang-Yue Zheng, Wei Lin Published: 2026 ABSTRACT ObjectiveThis study aimed to assess the prognostic value of preoperative peripheral blood-based inflammatory and nutritional indices in older adults diagnosed with gastric cancer (GC) undergoing radical gastrectomy and to develop a novel composite prognostic score.MethodsA retrospective single-center analysis of clinicopathologic data of 609 older adults diagnosed with GC who underwent radical gastrectomy at the Affiliated Hospital of Putian University between 2012 and 2020, was conducted. Multivariate Cox regression analysis was performed to identify independent prognostic factors. A composite score, termed the PNI-dNLR, was constructed using the prognostic nutritional index (PNI) and derived neutrophil-to-lymphocyte ratio (dNLR), and its predictive performance was assessed.ResultsMultivariate Cox regression identified both preoperative PNI (hazard ration [HR], 0.74; 95% confidence interval [CI], 0.57–0.97; p = 0.027) and dNLR (HR, 1.44; 95% CI, 1.06–1.94; p = 0.018) as independent prognostic indicators for overall survival (OS) and disease-free survival (DFS). The PNI-dNLR score, derived from these two variables, demonstrated favorable predictive performance as assessed by the Akaike information criterion, Bayesian information criterion, time-dependent concordance index, and time-dependent receiver operating characteristic curve analysis. The PNI-dNLR remained an independent predictor of OS and DFS in multivariate Cox regression models (p < 0.05). Further validation using least absolute shrinkage and selection operator-Cox regression, random survival forest, and survival tree modeling, along with intersecting features from multivariate Cox analysis, supported the prognostic significance of the PNI-dNLR score in this population.ConclusionPreoperative dNLR and PNI independently predicted long-term postoperative outcomes in older adults undergoing radical gastrectomy for GC. The combined PNI-dNLR score demonstrated predictive value, which need further prospective multicenter study conducting internal and external validation to confirm before clinic application for risk stratification, personalized prognostic assessment, and treatment planning in this patient population. Introduction Gastric cancer (GC) ranks fifth globally in both incidence and mortality, with approximately one million newly diagnosed cases and over 650,000 GC-related deaths reported annually.1,2 Although advancements in treatment, particularly radical gastrectomy combined with various adjuvant therapies, have contributed to improved survival rates and quality of life, the prognosis of GC remains poor due to factors such as the low rate of early-stage detection, marked biological heterogeneity, and a high propensity for distant metastasis.3 The global trend toward population aging has led to an increasing proportion of older individuals being diagnosed with malignancies, including GC, introducing significant societal, medical, and economic challenges.4 In addition to tumor-specific factors, older individuals often present with age-associated physiological decline, including multiple organ dysfunction, compromised immune response, and reduced tolerance to surgical stress, all of which contribute to variability in postoperative recovery and long-term survival outcomes. Consequently, the identification of reliable prognostic markers is essential to enhance the accuracy of long-term survival predictions and to inform individualized treatment strategies for older adults with GC. Emerging evidence suggests that systemic inflammatory responses and malnutrition are closely associated with the prognosis of GC.5–7 Inflammatory mechanisms play a key role in oncogenesis and tumor progression, while nutritional status influences immune competence. Several preoperative inflammatory indicators derived from peripheral blood cell counts, including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), derived neutrophil-to-lymphocyte ratio (dNLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI), have been consistently associated with disease progression and poor prognosis in individuals with gastric malignancies.8–10 Similarly, composite indices that integrate nutritional and immune parameters, such as the geriatric nutritional risk index (GNRI) and the prognostic nutritional index (PNI), have also been identified as independent prognostic factors in patients with GC.11,12 A previous study found that the combined biomarker of dNLR and PLR was associated with the outcomes of patients with advanced GC receiving anti-PD-1 antibody treatment.13 However, no study has clearly demonstrated the predictive value of PNI or dNLR for the long-term prognosis of older adult patients with GC after surgery, and there are no related studies that have constructed a PNI-dNLR combined scoring model for predicting the prognosis of older adult patients with GC after surgery. This study aimed to assess the prognostic value of preoperative peripheral blood-based inflammatory and nutritional indices in older adults diagnosed with GC undergoing radical gastrectomy and to develop a novel composite prognostic score. Materials and Methods Study Population Clinicopathologic data from consecutive older adults diagnosed with GC who underwent radical gastrectomy at the Affiliated Hospital of Putian University between 2012 and 2020 were retrospectively reviewed. Inclusion criteria were as follows: (a) age ≥ 65 years; (b) histopathological confirmation of primary gastric adenocarcinoma; (c) absence of peritoneal or distant metastasis as confirmed by intraoperative exploration; and (d) confirmation of R0 resection, as verified by postoperative pathological assessment. Exclusion criteria included: (a) presence of other malignancies; (b) presence of hematological malignancies or autoimmune disorders; (c) severe hepatic or renal dysfunction or other comorbidities contributing to poor nutritional status; (d) severe infections or other inflammatory conditions; (e) receipt of preoperative neoadjuvant therapy; (f) diagnosis of gastric stump cancer; and (g) incomplete clinicopathologic data. A total of 609 patients met the eligibility criteria and were included in the final study cohort. The median follow-up period were 60 months. Postoperative pathological staging was conducted based on the Eighth Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual.14 For older adults with advanced-stage GC, adjuvant chemotherapy regimens based on 5-fluorouracil (primarily oxaliplatin + capecitabine or oxaliplatin + S-1) were recommended.15 This study was approved by the Ethics Committee of the Affiliated Hospital of Putian University and conducted in accordance with the principles outlined in the Declaration of Helsinki. Written, informed consent was obtained from all participants. Definitions Older adults with GC were defined as those aged 65 years or older. Age and tumor size were categorized based on their respective median values: 70 years and 50 mm, respectively. dNLR was calculated as the ratio of the absolute neutrophil number to the difference between absolute total leukocyte and absolute neutrophil counts, a proxy for lymphocyte count.16 Body mass index (BMI) was categorized into three groups according to the World Health Organization standards: < 18.5 kg/m2, 18.5–24.9 kg/m2, and > 24.9 kg/m2. Postoperative complications were classified using the Clavien-Dindo (CD) classification system, with a CD grade of ≥ II defined as indicating severe postoperative complications.17 Measurement of Nutritional and Inflammatory Indicators Hematological and laboratory parameters were obtained within one week prior to surgery and were prospectively recorded in the GC database. These parameters included white blood cell count, neutrophil count, lymphocyte count, monocyte count, platelet count, and serum albumin level. Formulas used to calculate specific inflammatory and nutritional indices are presented in Supplementary Table 1. Based on 5-year OS outcomes, optimal cut-off values for NLR, LMR, PLR, dNLR, SII, SIRI, AISI, GNRI, and PNI were determined using X-tile software (V3.6.1). The identified cut-off values were 1.4, 4.4, 116.8, 2.2, 401.8, 0.5, 116.7, 96.0, and 46.1, respectively.18 Postoperative Follow-Up Follow-up assessments were conducted every three months during the first two years after surgery, and every six months from the third to the fifth post-operative year. The follow-up evaluations included physical examinations; laboratory tests such as complete blood count, biochemical profile, carcinoembryonic antigen (CEA), alpha-fetoprotein, and carbohydrate antigen 19–9; chest radiography; abdominal and pelvic ultrasonography or computed tomography; and annual endoscopic examinations. As of the final follow-up in December 2025, the overall follow-up rate was 95%. Statistical Analysis All statistical analyses were performed using R software, version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria). Categorical variables were presented as frequencies and percentages, while continuous variables were expressed as means with standard deviations or as medians with interquartile ranges, depending on data distribution. Categorical variables were compared using the chi-squared test or Fisher’s exact test, and continuous variables were analyzed using the Mann–Whitney test and the Kruskal–Wallis test. Based on the nature of data, Spearman correlation analysis was applied to assess relationships among indicators. The prognostic performance of individual indicators and the composite PNI-dNLR score was assessed using receiver operating characteristic (ROC) curve analysis, time-dependent ROC analysis, and the concordance index (C-index). Survival outcomes were assessed using the Kaplan–Meier (K–M) method, and comparisons between groups were made using the Log rank test. Restricted cubic spline (RCS) examined the relationship between independent variables and mortality risk. Univariable and multivariable Cox regression identified independent prognostic factors for OS and DFS, and validated the prognostic value of the PNI-dNLR score. Collinearity [tolerance (Tol), variance inflation factor (VIF)] and interactions were assessed. Model performance was evaluated using Akaike information criteria (AIC) and Bayesian information criterion (BIC) to balance accuracy and complexity. To further examine the predictive utility of the PNI-dNLR score, the following additional analyses were performed: least absolute shrinkage and selection operator Cox regression (LASSO-Cox) regression, random survival forest (RSF) modeling, and survival tree (ST) modeling. The Schoenfeld residuals method was used to test the proportional hazards assumption of the Cox model. The p values of all variables and the overall model PH test were all greater than 0.05, satisfying the proportional hazards assumption. The VIF variance inflation factor was used to assess collinearity, and the results showed that there was no multicollinearity among the included variables and no interference from extreme outliers. The LASSO-Cox model satisfies the core assumptions of Cox regression through the Schoenfeld residuals, Box-Tidwell test, and VIF test. It then selects the optimal λ coefficient by combining the LASSO penalty function with cross-validation, compressing redundant variables and reducing the risk of model overfitting, thereby completing the optimization and construction of the model. The RSF model, as a non-parametric ensemble model, does not require the proportional hazards assumption. Instead, it ensures the generalization ability and robustness of the model through the OOB error, cross-validation and resampling integration strategies. In the analysis concerning ST modeling, through outlier handling, stratified sampling, pruning optimization, and error analysis, there was no overfitting and the results were stable All tests were two-sided, and statistical significance was defined as p < 0.05. Results General Clinicopathologic Features A total of 609 patients with GC were included in this study, comprising of 459 males (75.4%) and 150 females (24.6%), with a median age of 70 years (interquartile range [IQR]: 67–74). Most patients had no documented preoperative comorbidities (n = 374; 61.4%) and presented with a BMI in the range of 18.5 to 24.9 kg/m2 (n = 453; 74.4%). Most participants were classified as American Society of Anesthesiologists (ASA) physical status grade II (n = 361; 59.3%). Tumors were predominantly located in the proximal stomach, with the majority measuring less than 5 cm and exhibiting mixed histological differentiation. Total gastrectomy was performed in most cases (n = 488; 80.1%). Open surgical procedures were more frequently employed (n = 354; 58.1%), compared to received laparoscopic approaches (n = 255; 41.9%). Postoperative pathological evaluation indicated that the most common pathological TNM (pTNM) classification was stage III (n = 308; 50.6%). Vascular and nerve invasion were observed in 26.9% and 23.2% of patients, respectively. Postoperative complications classified as CD grade II or higher occurred in 17.7% of the cohort. Adjuvant chemotherapy was administered to 49.4% of the cohort. The median follow-up duration was 60 months (IQR: 24–84 months), and the 5-year OS rate was 55.5% (n = 338) (Table 1).Table 1Baseline CharacteristicsAll (n=609)Sex, n (%) Female150 (24.6%) Male459 (75.4%)Age (years), n (%) <70283 (46.5%) ≥70326 (53.5%)Comorbidity, n (%) No374 (61.4%) Yes235 (38.6%)BMI (kg/m2), n (%) <18.581 (13.3%) 18.5–24.9453 (74.4%) >24.975 (12.3%)ASA, n (%) I209 (34.3%) II361 (59.3%) III39 (6.4%)Surgical approach, n (%) Laparoscopic255 (41.9%) Open354 (58.1%)Surgical procedure, n (%) Subtotal121 (19.9%) Total488 (80.1%)Tumor location, n (%) Upper283 (46.5%) Middle153 (25.1%) Lower134 (22.0%) Overlapping39 (6.4%)Tumor size (cm), n (%) <5338 (55.5%) ≥5271 (44.5%)Histological type, n (%) Differentiated309 (50.7%) Undifferentiated300 (49.3%)AJCC pT stage, n (%) T1124 (20.4%) T260 (9.8%) T3146 (24.0%) T4a279 (45.8%)AJCC pN stage, n (%) N0245 (40.2%) N191 (14.9%) N294 (15.4%) N3a117 (19.2%) N3b62 (10.2%)AJCC pTNM, n (%) I164 (26.9%) II137 (22.5%) III308 (50.6%)Vascular invasion, n (%) No445 (73.1%) Yes164 (26.9%)Perineural invasion, n (%) No467 (76.7%) Yes142 (23.3%)CD, n (%) 24.975 (12.3%)ASA, n (%) I209 (34.3%) II361 (59.3%) III39 (6.4%)Surgical approach, n (%) Laparoscopic255 (41.9%) Open354 (58.1%)Surgical procedure, n (%) Subtotal121 (19.9%) Total488 (80.1%)Tumor location, n (%) Upper283 (46.5%) Middle153 (25.1%) Lower134 (22.0%) Overlapping39 (6.4%)Tumor size (cm), n (%) <5338 (55.5%) ≥5271 (44.5%)Histological type, n (%) Differentiated309 (50.7%) Undifferentiated300 (49.3%)AJCC pT stage, n (%) T1124 (20.4%) T260 (9.8%) T3146 (24.0%) T4a279 (45.8%)AJCC pN stage, n (%) N0245 (40.2%) N191 (14.9%) N294 (15.4%) N3a117 (19.2%) N3b62 (10.2%)AJCC pTNM, n (%) I164 (26.9%) II137 (22.5%) III308 (50.6%)Vascular invasion, n (%) No445 (73.1%) Yes164 (26.9%)Perineural invasion, n (%) No467 (76.7%) Yes142 (23.3%)CD, n (%) 24.90.76 (0.48–1.21)0.247ASA IReferenceReference II1.85 (1.39–2.47)<0.0011.46 (1.04–2.03)0.027 III3.43 (2.19–5.39)<0.0011.55 (0.93–2.58)0.095Surgical approach OpenReferenceReference Laparoscope0.31 (0.24–0.42)<0.0010.65 (0.47–0.89)0.008Surgical procedure TotalReference Subtotal0.92 (0.68–1.25)0.592Tumor location UpperReference Middle0.80 (0.59–1.09)0.161 Lower0.94 (0.69–1.29)0.716 Overlapping1.57 (1.01–2.42)0.043Tumor size (cm) <5ReferenceReference ≥52.11 (1.66–2.68)<0.0010.96 (0.73–1.26)0.759Histological type DifferentiatedReferenceReference Undifferentiated2.11 (1.65–2.70)<0.0011.20 (0.90–1.58)0.210AJCC pT stage T1ReferenceReference T22.42 (1.10–5.30)0.0281.66 (0.73–3.75)0.227 T36.44 (3.49–11.90)<0.0012.22 (1.06–4.66)0.034 T4a10.20 (5.68–18.30)<0.0012.79 (1.34–5.82)0.006AJCC pN stage N0ReferenceReference N12.61 (1.64–4.15)<0.0011.79 (1.05–3.04)0.032 N25.23 (3.48–7.86)<0.0013.11 (1.91–5.07)<0.001 N39.74 (6.81–13.90)<0.0015.24 (3.28–8.39)<0.001Vascular invasion NoReferenceReference Yes2.41 (1.89–3.07)<0.0011.14 (0.86–1.51)0.373Perineural invasion NoReferenceReference Yes1.93 (1.49–2.49)<0.0010.98 (0.73–1.30)0.872CD 24.90.76 (0.48–1.21)0.247ASA IReferenceReference II1.85 (1.39–2.47)<0.0011.46 (1.04–2.03)0.027 III3.43 (2.19–5.39)<0.0011.55 (0.93–2.58)0.095Surgical approach OpenReferenceReference Laparoscope0.31 (0.24–0.42)<0.0010.65 (0.47–0.89)0.008Surgical procedure TotalReference Subtotal0.92 (0.68–1.25)0.592Tumor location UpperReference Middle0.80 (0.59–1.09)0.161 Lower0.94 (0.69–1.29)0.716 Overlapping1.57 (1.01–2.42)0.043Tumor size (cm) <5ReferenceReference ≥52.11 (1.66–2.68)<0.0010.96 (0.73–1.26)0.759Histological type DifferentiatedReferenceReference Undifferentiated2.11 (1.65–2.70)<0.0011.20 (0.90–1.58)0.210AJCC pT stage T1ReferenceReference T22.42 (1.10–5.30)0.0281.66 (0.73–3.75)0.227 T36.44 (3.49–11.90)<0.0012.22 (1.06–4.66)0.034 T4a10.20 (5.68–18.30)<0.0012.79 (1.34–5.82)0.006AJCC pN stage N0ReferenceReference N12.61 (1.64–4.15)<0.0011.79 (1.05–3.04)0.032 N25.23 (3.48–7.86)<0.0013.11 (1.91–5.07)<0.001 N39.74 (6.81–13.90)<0.0015.24 (3.28–8.39)<0.001Vascular invasion NoReferenceReference Yes2.41 (1.89–3.07)<0.0011.14 (0.86–1.51)0.373Perineural invasion NoReferenceReference Yes1.93 (1.49–2.49)<0.0010.98 (0.73–1.30)0.872CD 24.90.76 (0.48–1.21)0.2470.87 (0.54–1.40)0.5660.99 (0.61–1.62)0.981ASA IReferenceReferenceReference II1.85 (1.39–2.47)<0.0011.75 (1.26–2.43)0.0011.58 (1.14–2.19)0.006 III3.43 (2.19–5.39)<0.0013.32 (2.02–5.45)<0.0011.87 (1.11–3.13)0.018Surgical approach OpenReferenceReference Laparoscope0.31 (0.24–0.42)<0.0010.65 (0.48–0.89)0.008Surgical procedure TotalReferenceReference Subtotal0.92 (0.68–1.25)0.5921.70 (0.93–2.81)0.058Tumor location UpperReferenceReference Middle0.80 (0.59–1.09)0.1610.77 (0.55–1.06)0.110 Lower0.94 (0.69–1.29)0.7160.59 (0.35–0.97)0.039 Overlapping1.57 (1.01–2.42)0.0431.00 (0.63–1.58)0.994Tumor size (cm) <5ReferenceReference ≥52.11 (1.66–2.68)<0.0011.01 (0.78–1.32)0.933Histological Type DifferentiatedReferenceReference Undifferentiated2.11 (1.65–2.70)<0.0011.35 (1.04–1.76)0.025AJCC pTNM stage IReferenceReference II3.54 (1.99–6.31)<0.0013.18 (1.71–5.91)<0.001 III11.82 (7.10–19.68)<0.0019.61 (5.37–17.19)<0.001Vascular invasion NoReferenceReference Yes2.41 (1.89–3.07)<0.0011.27 (0.97–1.68)0.084Perineural invasion NoReferenceReference Yes1.93 (1.49–2.49)<0.0010.86 (0.64–1.16)0.319CD 24.90.76 (0.48–1.21)0.2470.87 (0.54–1.40)0.5660.99 (0.61–1.62)0.981ASA IReferenceReferenceReference II1.85 (1.39–2.47)<0.0011.75 (1.26–2.43)0.0011.58 (1.14–2.19)0.006 III3.43 (2.19–5.39)<0.0013.32 (2.02–5.45)<0.0011.87 (1.11–3.13)0.018Surgical approach OpenReferenceReference Laparoscope0.31 (0.24–0.42)<0.0010.65 (0.48–0.89)0.008Surgical procedure TotalReferenceReference Subtotal0.92 (0.68–1.25)0.5921.70 (0.93–2.81)0.058Tumor location UpperReferenceReference Middle0.80 (0.59–1.09)0.1610.77 (0.55–1.06)0.110 Lower0.94 (0.69–1.29)0.7160.59 (0.35–0.97)0.039 Overlapping1.57 (1.01–2.42)0.0431.00 (0.63–1.58)0.994Tumor size (cm) <5ReferenceReference ≥52.11 (1.66–2.68)<0.0011.01 (0.78–1.32)0.933Histological Type DifferentiatedReferenceReference Undifferentiated2.11 (1.65–2.70)<0.0011.35 (1.04–1.76)0.025AJCC pTNM stage IReferenceReference II3.54 (1.99–6.31)<0.0013.18 (1.71–5.91)<0.001 III11.82 (7.10–19.68)<0.0019.61 (5.37–17.19)<0.001Vascular invasion NoReferenceReference Yes2.41 (1.89–3.07)<0.0011.27 (0.97–1.68)0.084Perineural invasion NoReferenceReference Yes1.93 (1.49–2.49)<0.0010.86 (0.64–1.16)0.319CD